South Korea’s Celltrion to acquire Takeda portfolio

15 June 2020 - Deborah Wilkes

South Korean biopharmaceutical company Celltrion is acquiring a portfolio of prescription and OTC brands from Japan’s Takeda in a deal worth up to USD278 million.